Faecal Microbiota Transplantation is a simple, effective and safe treatment in the management of C. difficile infection in daily clinical practice
Copyright © 2022 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: Faecal microbiota transplantation (FMT) is a treatment supported by wide scientific evidence and proved to be very effective in the management of Clostridioides difficile infection (CDI). The objective of this study is to analyze its effectiveness and safety in a real clinical practice setting.
METHODS: Retrospective, single-center and descriptive observational study in which all FMT performed between May 2016 and December 2020 were included. Technical success was defined as the successful administration of the faecal preparation in the patient's gastrointestinal tract and clinical success the disappearance of diarrhoea in the first 72 h after the procedure with no relapse within the following 8 weeks after the therapy was started.
RESULTS: 15 FMT were performed in 13 patients. Median age was 79 years (range: 40-98 years); being 60% women and 33.3% depedent persons. The indication for FMT was recurrent CDI in 84.6%. All FMTs were performed by colonoscopy and from related donors. With a first procedure, the FMT was effective in 11 of 13 patients (84.61%; 95% CI; 54.55-98.07). Time until resolution of symptoms was less than 48 h in all cases. Post-transplant follow-up was 25.66 ± 17.5 months. No significant short or long-term complications were recorded at follow-up.
CONCLUSION: TMF is a simple, effective and safe procedure in CD infection, even in elderly patients or those with great comorbidities.
| Errataetall: |
CommentIn: Enferm Infecc Microbiol Clin (Engl Ed). 2023 Apr;41(4):203-205. - PMID 36737368 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Enfermedades infecciosas y microbiologia clinica (English ed.) - 41(2023), 4 vom: 19. Apr., Seite 206-210 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferre Aracil, Carlos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clostridioides difficile |
|---|
| Anmerkungen: |
Date Completed 07.04.2023 Date Revised 12.04.2023 published: Print-Electronic CommentIn: Enferm Infecc Microbiol Clin (Engl Ed). 2023 Apr;41(4):203-205. - PMID 36737368 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.eimce.2022.01.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351922849 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351922849 | ||
| 003 | DE-627 | ||
| 005 | 20231226052544.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eimce.2022.01.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM351922849 | ||
| 035 | |a (NLM)36681571 | ||
| 035 | |a (PII)S2529-993X(23)00006-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferre Aracil, Carlos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Faecal Microbiota Transplantation is a simple, effective and safe treatment in the management of C. difficile infection in daily clinical practice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2023 | ||
| 500 | |a Date Revised 12.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Enferm Infecc Microbiol Clin (Engl Ed). 2023 Apr;41(4):203-205. - PMID 36737368 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: Faecal microbiota transplantation (FMT) is a treatment supported by wide scientific evidence and proved to be very effective in the management of Clostridioides difficile infection (CDI). The objective of this study is to analyze its effectiveness and safety in a real clinical practice setting | ||
| 520 | |a METHODS: Retrospective, single-center and descriptive observational study in which all FMT performed between May 2016 and December 2020 were included. Technical success was defined as the successful administration of the faecal preparation in the patient's gastrointestinal tract and clinical success the disappearance of diarrhoea in the first 72 h after the procedure with no relapse within the following 8 weeks after the therapy was started | ||
| 520 | |a RESULTS: 15 FMT were performed in 13 patients. Median age was 79 years (range: 40-98 years); being 60% women and 33.3% depedent persons. The indication for FMT was recurrent CDI in 84.6%. All FMTs were performed by colonoscopy and from related donors. With a first procedure, the FMT was effective in 11 of 13 patients (84.61%; 95% CI; 54.55-98.07). Time until resolution of symptoms was less than 48 h in all cases. Post-transplant follow-up was 25.66 ± 17.5 months. No significant short or long-term complications were recorded at follow-up | ||
| 520 | |a CONCLUSION: TMF is a simple, effective and safe procedure in CD infection, even in elderly patients or those with great comorbidities | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clostridioides difficile | |
| 650 | 4 | |a Clostridium difficile | |
| 650 | 4 | |a Colonoscopia | |
| 650 | 4 | |a Colonoscopy | |
| 650 | 4 | |a Faecal microbiota transplantation | |
| 650 | 4 | |a Trasplante Microbiota Fecal | |
| 650 | 4 | |a Tratamiento | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a El Hajra Martínez, Ismael |e verfasserin |4 aut | |
| 700 | 1 | |a Vera Mendoza, MaríaI Sabel |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos Martínez, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Muñez Rubio, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Cruz, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Matallana Royo, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a García-Maseda, Sarela |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez Romero, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez Ruiz, Rocío |e verfasserin |4 aut | |
| 700 | 1 | |a Calleja Panero, José Luis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Enfermedades infecciosas y microbiologia clinica (English ed.) |d 2012 |g 41(2023), 4 vom: 19. Apr., Seite 206-210 |w (DE-627)NLM220666776 |x 2529-993X |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:4 |g day:19 |g month:04 |g pages:206-210 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eimce.2022.01.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 4 |b 19 |c 04 |h 206-210 | ||